Table 1 Demographics, chronic underlying diseases, baseline clinical characteristics, and outcomes of patients with stool samples collected in the first two weeks after symptoms onset.
Variables, N (%) | With RNA in feces (N = 16) | Without RNA in feces (N = 31) | P-valueb |
|---|---|---|---|
Age (median [IQR]) | 60 (47–71) | 62 (52–70) | 0.544 |
Male sex | 8 (50.0%) | 21 (67.7%) | 0.236 |
Chronic kidney disease | 1 (6.3%) | 4 (12.9%) | 0.648 |
Chronic liver disease | 1 (6.3%) | 1 (3.2%) | 1.000 |
Connective tissue disease | 1 (6.3%) | 0 (0%) | 0.340 |
Solid organ transplantation | 3 (18.8%) | 1 (3.2%) | 0.108 |
Diarrhea | 5 (31.3%) | 7 (22.6%) | 0.725 |
Vomiting | 0 (0%) | 0 (0%) | [..] |
Cough | 11 (68.8%) | 19 (61.3%) | 0.614 |
Odynophagia | 2 (12.5%) | 1 (3.2%) | 0.264 |
Headache | 6 (37.5%) | 7 (23.3%) | 0.328 |
Anosmia | 3 (18.8%) | 6 (19.4%) | 1.000 |
Dysgeusia | 4 (25.0%) | 8 (25.8%) | 1.000 |
Fever | 9 (56.3%) | 23 (74.2%) | 0.211 |
SpO2 < 95% at diagnosis | 3 (18.8%) | 13 (43.3%) | 0.095 |
qSOFA ≥ 2 | 0 (0%) | 2 (6.5%) | 0.541 |
Pneumonia | 12 (75.0%) | 31 (100%) | 0.010 |
Remdesivira | 2 (12.5%) | 14 (45.1%) | 0.314 |
Leucocytes > 11,000/μL | 1 (6.7%) | 1 (3.2%) | 1.000 |
Neutrophils > 7,500/μL | 3 (18.8%) | 3 (9.7%) | 0.395 |
Lymphocytes < 1000/µL | 9 (56.3%) | 14 (45.2%) | 0.471 |
Creatinine > 1.3 mg/dL | 4 (25.0%) | 4 (12.9%) | 0.416 |
CRP > 100 mg/L | 2 (12.5%) | 6 (20.0%) | 0.694 |
LDH > 300 UI/L | 4 (26.7%) | 13 (43.3%) | 0.277 |
SARS-CoV-2 RNAemia | 1 (6.7%) | 2 (7.1%) | 1.000 |
SARS-CoV-2 RNA in NP swabs (Log10 copies/mL) | 7.10 (4.46–9.07) | 7.81 (6.13–9.01) | 0.351 |
ARDS | 1 (6.3%) | 1 (3.2%) | 1.000 |
IMV | 0 (0%) | 1 (3.2%) | 1.000 |
ICU admission and/or death | 1 (6.3%) | 1 (3.2%) | 1.000 |
Basal score | |||
Moderate | 16 (100%) | 31 (100%) | [..] |
Severe | 0 (0%) | 0 (0%) | [..] |
Final score | |||
Moderate | 15 (93.8%) | 30 (96.8%) | 1.000 |
Severe | 1 (6.3%) | 1 (3.2%) | 1.000 |
